Abstract | OBJECTIVES: MATERIAL AND METHODS: In patients with epilepsy diagnosed within previous 3 months, investigators selected CBZ (600 mg/day) or VPA (1250 mg/day) as preferred therapy based on the patient's clinical presentation. Based on investigators' treatment choice, patients (n=613) were assigned to the CBZ or VPA treatment branch. Within each branch, patients were randomized to double-blind treatment with the traditional antiepileptic drugs (CBZ or VPA), TPM 100 mg/day, or TPM 200 mg/day. Patients continued double-blind treatment until exiting the study or until 6 months after last patient randomized. RESULTS: No statistically significant differences between fixed doses of TPM and CBZ or VPA were observed in efficacy measures: time to exit, time to first seizure, and the proportion of patients seizure-free during the last 6 months of treatment. TPM 100 mg/day was associated with the fewest discontinuations due to adverse events. CONCLUSION: In patients with newly diagnosed epilepsy, an initial target dose of TPM 100 mg/day is at least as effective as therapeutic doses of CBZ and VPA.
|
Authors | M D Privitera, M J Brodie, R H Mattson, D W Chadwick, W Neto, S Wang, EPMN 105 Study Group |
Journal | Acta neurologica Scandinavica
(Acta Neurol Scand)
Vol. 107
Issue 3
Pg. 165-75
(Mar 2003)
ISSN: 0001-6314 [Print] Denmark |
PMID | 12614309
(Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Anticonvulsants
- Topiramate
- Fructose
- Carbamazepine
- Valproic Acid
|
Topics |
- Administration, Oral
- Adolescent
- Adult
- Aged
- Anticonvulsants
(administration & dosage, pharmacology)
- Carbamazepine
(administration & dosage, pharmacology)
- Child
- Double-Blind Method
- Epilepsy
(drug therapy, pathology)
- Female
- Fructose
(administration & dosage, analogs & derivatives, pharmacology)
- Humans
- Male
- Middle Aged
- Seizures
- Topiramate
- Treatment Outcome
- Valproic Acid
(administration & dosage, pharmacology)
|